Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001617201-26-000008·Janux Therapeutics, Inc.
Schedule 13G ownership disclosure
Janux Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 47103J105
Event date: 2026-11-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- W. Lawrence Hawkins
Shares: 3,150,450 · Class: 5.15%
- Prosight Fund, LP
Shares: 155,022 · Class: 0.25%
- Prosight Plus Fund, LP
Shares: 525,319 · Class: 0.86%
- Prosight Management, LP
Shares: 3,144,200 · Class: 5.14%
- Prosight Partners, LLC
Shares: 3,144,200 · Class: 5.14%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001617201-26-000008
- Form type
- SCHEDULE 13G/A
- Filer
- Janux Therapeutics, Inc.
- CIK
- CIK 1817713
- Filed
- Nov 13, 2026
- Reporting period
- Nov 10, 2026
- Description
- Schedule 13G beneficial ownership